Does the November share price for Hikma Pharmaceuticals PLC (LON:HIK) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then ...
Hikma Pharmaceuticals Plc (LON:HIK) said it is “successfully” launching new products as it reiterated full-year guidance for 2019. The FTSE 100-listed pharma group said, in a trading statement, that ...
StockMarketWire.com - Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 1900p (from 1800p).
Hikma Pharmaceuticals announced the appointment of Henriette Nielsen to the newly-created role of chief transformation officer on Monday.
Thomas Cook: Numis downgrades to add with a target price of 159p.
Hikma Pharmaceuticals told shareholders its year had begun with an "encouraging start" on Friday, as they gathered for the annual general meeting, with the global Injectables business particularly said to be performing "well".
Hikma Pharmaceuticals' US subsidiary West-Ward Pharmaceuticals has launched Methotrexate for injection in two doses for the treatment of various cancers.
(WebFG News) - Hikma Pharmaceuticals has launched a generic injectable product to counter a shortage in the US market for products to counter heart problems associated with commonly prescribed chemotherapy drug.
Hikma Pharmaceuticals announced on Thursday that its wholly-owned US subsidiary West-Ward Pharmaceuticals has launched the palonosetron hydrochloride injection at 0.25mg/2mL.
Generic drug maker Hikma Pharmaceuticals said its US subsidiary West-Ward had launched Ritonavir Tablets, the first AB-rated generic to Norvir tablets.
Antofagasta plc: Canaccord upgrades to buy with a target price of 1,090p.
A $920m impairment charge on Hikma Pharmaceuticals' West-Ward Columbus business led to the company reporting a hefty $738m full year pre-tax loss on Wednesday.
Generic drug-maker Hikma Pharmaceuticals will carry out a clinical trial of its generic version of GlaxoSmithKline's Advair Diskus asthma drug after consultation with the US drug regulator.
ITV: Barclays downgrades to equal weight with a target price of 180p.
Hikma Pharmaceuticals announced on Tuesday that its board has appointed Sigurdur 'Siggi' Olafsson as its chief executive officer.
Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and development.
Hikma Pharmaceuticals is likely to disappoint with its outlook for the coming year, Jefferies analysts feared, downgrading the drugmaker to 'underperform'.
Hikma Pharmaceuticals has reached a licensing agreement with South Korea-based Celltrion for Truxima ((rituximab), the first biosimilar monoclonal antibody in oncology to be granted European marketing authorisation.
Hikma Pharmaceuticals has launched its own version of an acute injected treatment for migraine headaches, dihydroergotamine mesylate.
West-Ward's Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
According to IMS Health, US sales of Dihydroergotamine Mesylate Injection, USP were approximately $34.8 million in the 12 months ending October 2017.
Riad Mechlaoui, Chief Executive Officer of Injectables said, "We are pleased to be adding Dihydroergotamine Mesylate Injection, USP to our Injectables portfolio in the US. We have a large portfolio of products and a pipeline of differentiated products to support future growth."
Shares of FTSE 250-listed pharma firm Hikma Pharmaceuticals dropped in early trading on Tuesday after it announced the acquisition of products to the tune of $3m from a German partner.